ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
MindMed Initiates Dosing in Human Safety Study of Opioid Addiction Treatment
April 20, 2020Mind Medicine has begun dosing the first subject in an additional Phase 1 human safety trial of 18-MC. The safety trial has commenced on time and as scheduled, even during the COVID-19 pandemic. -
MindMed Advances Potential Treatment for Opioid Addiction
March 30, 2020Mind Medicine announced the company has begun enrollment in further human safety studies of 18-MC, the company's orally-active drug candidate for the treatment of opioid use disorders.
Pharma Sources Insight January 2025
